Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,536 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,903 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05656573 | CART-PSMA Cells for Advanced Prostate Cancer | recruiting | Phase 1 | 20 | Nova Therapeutics LLCINDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06683066 | Study on Human Bioequivalence of Triprerelin Acetate for Injection | recruiting | Phase 1 | 120 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03724747 |
| completed |
| Phase 1 |
| 63 |
| BayerINDUSTRY |
| 3 |
| Nov 8, 2024 |
| clinicaltrials |
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy(LuTectomy) | active not recruiting | Phase 1 / Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06663007 | RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure | recruiting | Phase 1 / Phase 2 | 72 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03776968 | A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics | completed | Phase 1 | 47 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04978675 | An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06566989 | A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) | completed | Phase 1 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT04291664 | PK and Dose Escalation and Expansion Study of DST-2970 | terminated | Phase 1 | 26 | DisperSol Technologies, LLCINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06554639 | A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011) | completed | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT02555397 | Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer | completed | Phase 1 | 15 | Henry Ford Health SystemOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04060394 | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | completed | Phase 1 / Phase 2 | 49 | Laekna LimitedINDUSTRY | 2 | Oct 10, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05156905 | Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 6 | University of California, San DiegoOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT01774071 | Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | terminated | Phase 1 / Phase 2 | 30 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 26, 2024 | clinicaltrials |
| NCT03558711 | PSMA-PET/CT for Prostate Cancer(NGP1) | completed | Phase 1 | 6 | University Hospital, GhentOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients | terminated | Phase 1 | 60 | University of ChicagoOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | withdrawn | Phase 1 / Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02566772 | Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer | completed | Phase 1 | 130 | Taiho Oncology, Inc.INDUSTRY | 4 | Sep 3, 2024 | clinicaltrials |
| NCT00321698 | Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for Localized Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06343038 | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study(PROGNOSTICS) | recruiting | Phase 1 | 25 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 30 | Biosplice Therapeutics, Inc.INDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma | terminated | Phase 1 | 14 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | completed | Phase 1 / Phase 2 | 49 | Astex Pharmaceuticals, Inc.INDUSTRY | 4 | Aug 2, 2024 | clinicaltrials |
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC | terminated | Phase 1 | 11 | Swiss Cancer InstituteOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06237491 | The Safety and Dosimetry Study of 177Lu-LNC1003 Injection | unknown | Phase 1 | 12 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 0 | Jul 24, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT04701021 | TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy | completed | Phase 1 | 12 | Ultimovacs ASAINDUSTRY | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05578820 | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid | completed | Phase 1 | 21 | Gene Surgery LLCINDUSTRY | 1 | Jul 1, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04284761 | A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer(Biolen-PC) | completed | Phase 1 | 17 | Alessa Therapeutics Inc.INDUSTRY | 3 | Jun 24, 2024 | clinicaltrials |
| NCT03276572 | Phase I Trial of 225Ac-J591 in Patients With mCRPC | completed | Phase 1 | 32 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03066154 | Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer(DOP) | terminated | Phase 1 | 24 | The Netherlands Cancer InstituteOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT02933255 | PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 31, 2024 | clinicaltrials |
| NCT02184533 | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | completed | Phase 1 | 15 | Stanford UniversityOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | terminated | Phase 1 | 52 | ExelixisINDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT03177460 | Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06081686 | Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer | unknown | Phase 1 / Phase 2 | 32 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | May 2, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT04086966 | PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study | completed | Phase 1 | 10 | University of Alabama at BirminghamOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Nov 15, 2024source: clinicaltrials